


Innovations powered by **X**BIO™ technology

# Next Science Limited AGM Presentation

May 6, 2020

George Savvides Chairman



**NEXT SCIENCE®**

ASX: NXS

# 2019 Strategic Priorities - Review

- X BIO application research
- Product development
- Regulatory submissions and approvals
- Product testing of our X BIO products in lab and clinical environments
- Commissioning new product manufacturing
- Sales, marketing and key partner performance



WIP






# Judith Mitchell Managing Director

# The Science – disrupting the biofilm


“80% of infections in Humans are in a biofilm” (CDC 2011)

## The Solution – Xbio™ Technology



### Deconstruct the bacterial biofilm barrier

Next Science's Xbio technology breaks the ionic bonds that hold the biofilm together. The polymers are then pulled into solution, effectively dissolving the biofilm barrier.



### Destroy the bacterial within, through cell lysis<sup>1</sup>

With the barrier dissolved, bacteria are exposed and more vulnerable to attack. Bacteria enveloped by Xbio technology experience cell lysis and are destroyed. Cell lysis is non-discriminatory destroying gram-positive and gram-negative bacteria, persister cells, and spores. There is no known resistance mechanism to cell lysis.



### Defend from recolonisation

The periodic release of bacteria from biofilms has been linked to chronic relapsing infections.<sup>2</sup> Disrupting and destroying the biofilm barrier can reduce the rate of biofilm recurrence by up to 1,000 times, effectively defending against recolonization.<sup>3</sup> Unlike other agents that claim to destroy biofilms, there is no known evidence of bacterial resistance to the Xbio technology.


Xbio™ is the only non-toxic solution to deconstruct the bacteria's protective barrier. We've applied material science innovation to physically deconstruct the bacteria's protective structures, exposing and then eradicating bacteria through cell lysis<sup>1</sup>, rather than using toxic or resistance building ingredients.

# The opportunities – prevention and treatment

Biofilms, bacteria, fungus and viruses pose a far-reaching threat to humans, animals and the environment

## DEVICE-RELATED INFECTIONS

- 1) Ventricular derivations
- 2) Contact lens
- 3) Mouthwash
- 4) Endotracheal tubes
- 5) Vascular central catheters
- 6) Tissue fillers, breast implants
- 7) Peripheral vascular catheters
- 8) Prosthetic cardiac valves, pacemakers and vascular grafts
- 9) Urinary catheters
- 10) Orthopedic implants and prosthetic joints




## TREATMENT AND PREVENTION OPPORTUNITIES

- 11) Acne and skin health
- 12) Chronic otitis media, chronic sinusitis
- 13) Chronic tonsillitis, dental plaque, chronic laryngitis, periodontitis, infection prevention
- 14) Endocarditis
- 15) Lung infections including pneumonia and cystic fibrosis
- 16) Kidney stones
- 17) Biliary tract infection
- 18) Urinary tract infection
- 19) Vaginosis
- 20) Osteomyelitis
- 21) Surgical site infections
- 22) Chronic wounds

- Products developed and/or available
- In development
- Active research underway
- No research at this time



## Our journey so far: a disruptive technology building market acceptance and growing revenues while creating new standards of care







“Helping patients daily while broadening and strengthening our patent portfolio to support our revenue growth ambitions” *J Mitchell Managing Director*

Over 130,000 patients treated with Xbio technology

# 2019 Achievements


- Company listed in April 2019
- Grew Sales 43% for the year
- Acquired a new partner for ENT (Grace Medical), Clinic based skin care in Australia (AST)
- Expanded the patent portfolio to 25 patents (April 2020)
- Discovered two new technologies providing a wider pathway for product development for dermatology treatments and for respiratory inflammation as well as infection.

# Products contributing to 2019 revenues

Product	Commercial Pathway	Application	Total addressable market
Bactisure Surgical Lavage 	Global Distribution through Zimmer Biomet	Treatment of infected surgical cavities & implants	500,000 – 1 Million patients globally annually
BlastX Antimicrobial Wound Gel 	Global Distribution 3M KCI Advanced Wound Care	Treatment of chronic wounds: Foot & Leg Ulcers, Bedsores and Pressure Ulcers	10 Million patients globally 6 million patients (US only) annually
SurgX Sterile antimicrobial wound gel 	NXS distribution network in the US	Prevention of infection in surgical incisions. Used in the Operating room	58 Million procedures in the US annually
Acne Gel and cream 	Advanced Skin Technologies Distributorship for Australia	Topical treatment of acne	Australian clinic market (1500) affiliated clinics



# 2020 plan: 5 product launches, growing evidence, growing revenue





# XPerience Surgical Rinse



XPerience Surgical Wash is packaged as a sterile solution in a 500mL Polypropylene bag.. The solution is then used to irrigate the surgery site replacing some of the saline rinses.

- Exceptionally effective against all known pathogens
  - MRSA
  - Pseudomonas
  - Candida fungi
  - C.acne
  - E.coli
  - S. epidermis
- Active for > 5 hours




With a total addressable market of \$15B, this is Next Science most important launch in 2020



# 2020 Pipeline of new product launches

Product	Target Launch	Commercial Pathway	Application	Total addressable market
Non Salicylic Acid Acne Cream & Cleanser 	March 2020	tbh skin care (ANZ) (Online marketing company)	Topical treatment of acne	Target audience 1.5 Million female teenagers in Australia.
Biofilm effective Disinfectant for Hard Surfaces	H2 2020	TBA	Walls, floors, hospital furniture and fittings	Global surface disinfectant market \$800 Million annually
XPerience Surgical Rinse 	2H 2020	NXS distribution network in the US Distribution partners outside the US	Intraoperative rinse in any surgical procedure	110 Million procedures globally

# 2020 Pipeline of new product launches

Product	Target Launch Date	Commercial Pathway	Application	Total addressable market
TorrentX Wound Wash 	2H 2020	Partnered with Triad Life Sciences with the launch of their new tissue substitute product	Topical wash for treatment of chronic wounds: foot & leg ulcers in preparation for a tissue substitute	US Skin substitute market was \$800M in 2019. This market is reimbursed by CMS
Middle Ear Wash 	Q4 2020/Q1 2021	TBA	Chronic middle ear infection being treated with tympanoplasty	3 Million surgeries in the US per annum
RipRecovery Hand Repair 	Delayed until COVID19 economic recovery is established	Direct Online marketing in the US	Skin Repair cream for Elite Athletes	4 Million cross fit devotees globally



# 2020 deliverables

- Expand the product range to 9 products
- Continued market expansion and penetration of existing products with partners
  - European approval for Bactisure
  - CE Mark expected for BlastX
- Build up of the 3<sup>rd</sup> party network of independent Surgical Sales representatives for the distribution of the Infection Prevention products: SurgX and XPerience
- Advancement in pharma development program including human trials in topical treatment of skin cancer and animal trials in lung treatments for respiratory infection and inflammation

# Pharma developments

- Topical treatment of Skin cancer advanced to Phase II clinical trials by Q1 2021
- Pre IND submission in COVID19 FDA fast track for Respiratory infection/inflammation nebulized treatment, with an Animal Study Q2/3 2020.
- Pre IND in Orphan pathway – Topical treatment of Hidradenitis Suppurativa (inflammatory skin disease) by Q4, 2020

# Outlook – building on our science and our clinical history

Our efforts this year will be focused on;

- Launching 5 new products
- Increasing our regulatory approvals and clinical evidence
- Assisting our partners with expanded sales forces to increase the market penetration and coverage in our existing products
- Q4 goal to be in the market with 8 products with multiple pathways to customers

Build awareness, expand clinical  
evidence and grow revenues

# NEXT SCIENCE<sup>®</sup>

Break through biofilm.

investorqueries@nextscience.com | +61 2 8607 5125 | NextScience.com

**Authorised by the Next Science Board**

Suite 1902 Tower A  
821 Pacific Highway  
Chatswood NSW 2067

Additional biofilm education can be found at: [biofilm.healthcare](http://biofilm.healthcare)